S
Steven P. LaRosa
Researcher at Brown University
Publications - 37
Citations - 3062
Steven P. LaRosa is an academic researcher from Brown University. The author has contributed to research in topics: Sepsis & Drotrecogin alfa. The author has an hindex of 19, co-authored 36 publications receiving 2865 citations. Previous affiliations of Steven P. LaRosa include Cleveland Clinic & Eli Lilly and Company.
Papers
More filters
Journal ArticleDOI
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
Steven M. Opal,Pierre-François Laterre,Bruno François,Steven P. LaRosa,Derek C. Angus,Jean-Paul Mira,Xavier Wittebole,Thierry Dugernier,Dominique Perrotin,Mark Tidswell,Luis Jauregui,Kenneth Krell,Jan Pachl,Takahashi Takeshi,Claus Peckelsen,Edward Cordasco,Chia-Sheng Chang,Sandra Oeyen,Naoki Aikawa,Tatsuya Maruyama,Roland M. H. Schein,Andre C. Kalil,Marc Van Nuffelen,Melvyn Lynn,Daniel P. Rossignol,Jagadish Gogate,Mary B. Roberts,Mary B. Roberts,Janice L. Wheeler,Jean Louis Vincent +29 more
TL;DR: Among patients with severe sepsis, the use of eritoran, compared with placebo, did not result in reduced 28-day mortality, and no significant differences were observed in any of the prespecified subgroups.
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis
Steven M. Opal,Pierre-François Laterre,Bruno François,Steven P. LaRosa,Derek C. Angus,Jean-Paul Mira,Xavier Wittebole,Thierry Dugernier,Dominique Perrotin,Mark Tidswell,Luis Jauregui,Kenneth Krell,Jan Pachl,Takahashi Takeshi,Claus Peckelsen,Edward Cordasco,Chia-Sheng Chang,Sandra Oeyen,Naoki Aikawa,Tatsuya Maruyama,Roland M. H. Schein,Andre C. Kalil,Marc Van Nuffelen,Melvyn Lynn,Daniel P. Rossignol +24 more
TL;DR: Steven M. Opal, MDPierre-Francois Laterre, MDBruno Francois, MDSteven P. LaRosa, MDDerek C. Kalil, MD, MPHMarc Van Nuffelen, MDMelvyn Lynn, PhDDaniel P. Rossignol, PhDJogadish Gogate, PhDMary B. Roberts, MSJanice L. Wheeler, BS, RNJean-Louis Vincent, MD as discussed by the authors
Journal ArticleDOI
A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation
Jean Louis Vincent,Mayakonda K. Ramesh,David Ernest,Steven P. LaRosa,Jan Pachl,Naoki Aikawa,Eric Hoste,Howard Levy,Joe Hirman,Marcel Levi,Mradul Kumar Daga,Demetrios J. Kutsogiannis,Mark Crowther,Gordon R. Bernard,Jacques Devriendt,Joan Vidal Puigserver,Daniel U. Blanzaco,Charles T. Esmon,Joseph E. Parrillo,Louis Guzzi,Seton J. Henderson,Chaicharn Pothirat,Parthiv Mehta,Jawed Fareed,Deepak Talwar,Kazuhisa Tsuruta,Kenneth J. Gorelick,Yutaka Osawa,Inder Kaul +28 more
TL;DR: ART-123 is a safe intervention in critically ill patients with sepsis and suspected disseminated intravascular coagulation and evidence suggestive of efficacy supporting further development of this drug in sepsi-associated coagulopathy is provided.
Journal Article
The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000)
Gordon R. Bernard,Steven P. LaRosa,Pierre-François Laterre,Eugene Wesley Ely,Jean-François Dhainaut,Charles J. Fisher,A Lopez-Rodriguez,Jeff Helterbrand,Jay S. Steingrub,Gary Garber,J. L. Vincent +10 more
Journal ArticleDOI
Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
Mark Tidswell,William Tillis,Steven P. LaRosa,Melvyn Lynn,AE Wittek,Richard Kao,Janice L. Wheeler,Jagadish Gogate,Steven M. Opal +8 more
TL;DR: The observed trend toward a lower mortality rate at the 105-mg dose, in subjects with severe sepsis and high predicted risk of mortality, should be further investigated.